bioAffinity Technologies Highlights Importance of Link Between Early Lung Cancer Detection and Curative Treatment During National Lung Cancer Awareness Month
Business Wire•29/10/2026•08:00 ET
0
Key Highlights
- ➤CyPath Lung showed 92% sensitivity, 87% specificity, and 88% accuracy in published trial
- ➤CyPath Lung delivered 99% negative predictive value in high-risk patients with small nodules
- ➤CyPath Lung is marketed as a Laboratory Developed Test by Precision Pathology Laboratory Services
- ➤bioAffinity will present CyPath Lung benefits at North Carolina’s November 5 Battle of the Blues event
Expert Statements
Maria Zannes, President and CEO of bioAffinity Technologies
“During National Lung Cancer Awareness Month, it is important to highlight the fact that lung cancer diagnosis and treatment is advancing at a rapid pace. We are honored to be joining patient advocates and the dedicated physicians who play a crucial part in these advancements”
Maria Zannes, President and CEO of bioAffinity Technologies
“Early lung cancer detection can lead to curative therapy. Much has changed – for the better – since my father died at age 39 of lung cancer. We are happy to be part of this good-news story.”
bioAffinity Technologies Highlights Importance of Link Between Early Lung Cancer Detection and Curative Treatment During National Lung Cancer Awareness Month
Benefits of CyPath® Lung to be shared with North Carolina patient advocacy and healthcare community at November 5 "Battle of the Blues" Event
Get started
Create a free account to read the full story.